CHARACTERIZATION OF THE INVIVO BEHAVIOR OF A CONTROLLED-RELEASE FORMULATION OF LEVODOPA (SINEMET CR)

被引:42
|
作者
WILDING, IR
HARDY, JG
DAVIS, SS
MELIA, CD
EVANS, DF
SHORT, AH
SPARROW, RA
YEH, KC
机构
[1] UNIV NOTTINGHAM,SCH PHARM,DEPT PHARMACEUT SCI,NOTTINGHAM NG7 2RD,ENGLAND
[2] QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND
[3] MERCK SHARP & DOHME LTD,W POINT,PA 19486
关键词
SINEMET CR; LEVODOPA; CARBIDOPA; GAMMA-SCINTIGRAPHY; GASTROINTESTINAL TRANSIT; ABSORPTION;
D O I
10.1097/00002826-199108000-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The gastrointestinal transit and systemic absorption of Sinement CR(50-200) controlled-release tablets and standard Sinemet (25-100) immediate-release (IR) tablets have been studied in fasted and fed healthy human subjects. Both formulations were labelled with a gamma-emitting radionuclide and their gastric emptying, colon arrival and in vivo disintegration profiles monitored using gamma scintigraphy. The IR dosage forms were found to disperse soon after administration and to empty rapidly from both fasted and fed stomachs. Erosion of the CR system was independent of food or stomach pH. The CR tablet was observed to disintegrate fully in the gastrointestinal (GI) tract, resulting in complete release of levodopa over a 3-4 h time period. Considerable intersubject variation was found to exist for levodopa absorption. Absorption was more protracted with Sinemet CR than with standard Sinemet, due to the controlled release characteristics of the tablet matrix. There was no rapid initial absorption phase and instead, a gradual build-up in the absorption profile occurred.
引用
收藏
页码:305 / 321
页数:17
相关论文
共 50 条
  • [21] A COMPARISON OF THE EFFECTS OF CONTROLLED-RELEASE LEVODOPA (MADOPAR CR) WITH CONVENTIONAL LEVODOPA IN LATE PARKINSONS-DISEASE
    MACMAHON, DG
    SACHDEV, D
    BODDIE, HG
    ELLIS, CJK
    KENDAL, BR
    BLACKBURN, NA
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (03): : 220 - 223
  • [22] FORMULATION OF CONTROLLED-RELEASE PRODUCTS
    ROBINSON, JR
    GAUGER, LJ
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1986, 78 (04) : 676 - 681
  • [23] Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®)
    Hsu, Ann
    Yao, Hsuan-Ming
    Gupta, Suneel
    Modi, Nishit B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09): : 995 - 1003
  • [24] INVITRO AND INVIVO CORRELATION FOR CONTROLLED-RELEASE FORMULATION OF D-CHLORPHENIRAMINE MALEATE
    KATORI, N
    OKUDAIRA, K
    AOYAGI, N
    TAKEDA, Y
    UCHIYAMA, M
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1991, 14 (10): : 567 - 575
  • [25] THERAPY WITH CONTROLLED-RELEASE LEVODOPA - MODERATORS SUMMARY
    RINNE, UK
    NEUROLOGY, 1989, 39 (11) : 95 - 95
  • [26] CONTROLLED-RELEASE CARBIDOPA LEVODOPA IN THE TREATMENT OF PARKINSONISM
    HUTTON, JT
    DIPPEL, RL
    BIANCHINE, JR
    STRAHLENDORF, HK
    MEYER, PG
    CLINICAL NEUROPHARMACOLOGY, 1984, 7 (02) : 135 - 139
  • [27] Pharmacokinetic profile of levodopa after repeated daily dosing of levodopa/carbidopa/entacapone 200/50/200mg (Stalevo®) compared with controlled-release levodopa/carbidopa 200/50mg (Sinemet® CR)
    Sauramo, Annamari
    Korpela, Kirsi
    Vahteristo, Mikko
    Kuoppamaki, Mikko
    Kailajarvi, Marita
    Lehtinen, Terhi
    Ellmen, Juba
    ANNALS OF NEUROLOGY, 2008, 64 : S51 - S52
  • [28] CONTROLLED-RELEASE COPRECIPITATES - FORMULATION CONSIDERATIONS
    KHAN, MA
    KARNACHI, AA
    SINGH, SK
    SASTRY, SV
    KISLALIOGLU, SM
    BOLTON, S
    JOURNAL OF CONTROLLED RELEASE, 1995, 37 (1-2) : 131 - 141
  • [29] CONTROLLED-RELEASE TABLET FORMULATION OF ISONIAZID
    JAIN, NK
    KULKARNI, K
    TALWAR, N
    PHARMAZIE, 1992, 47 (04): : 277 - 278
  • [30] A NEW CONTROLLED-RELEASE FORMULATION OF ALBUTEROL
    POWELL, ML
    WEISBERGER, M
    DOWDY, Y
    GURAL, R
    SYMCHOWICZ, S
    PATRICK, JE
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1986, 77 (01) : 152 - 152